The role of PARP inhibitor combination therapy in ovarian cancer
Helen Hockings(St Bartholomew's Hospital), Rowan Miller(Queen Mary University of London)
Cited by 38
Related Papers
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
|Nature Communications|2016|386
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|381